Increasing number of research activities and R spending by pharmaceutical and biotechnology companies, rising prevalence of HIV/AIDS, growing proteomics market, growing number of industry-academic research collaborations, increasing demand for personalized medicine, and new product launches are expected to drive the growth of the market in the coming years.Key Factors Driving Market Growth:The growth of the overall market can be attributed to the increasing number of research activities and R spending by pharmaceutical and biotechnology companies, rising prevalence of HIV/AIDS, and growing proteomics market are key factors driving the demand for western blotting instruments and consumables, increasing demand for personalized medicine, and new product launches are some of the other factors driving the growth of this market.Revenue Growth Analysis:The western blotting market is projected to reach USD 730.7 Million by 2021 from USD 574.8 Million in 2016, at a CAGR of 4.9% in the next five years (2016 to 2021).Browse in-depth TOC on “Western Blotting Market”132 – Tables41 – Figures169 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235810711Don’t miss out on business opportunities in Western Blotting Market :In the coming years, the market is expected to witness the highest growth in the Asia-Pacific region.This can be attributed to increasing government interest in biomedical & biotechnology industry in China, government initiatives supported by funding in Japan, growing funding for agriculture research in India, increasing diagnosis and related funding in Australia, and growing prevalence of herpes simplex virus (HSV) in southeast Asia.Download PDF Brochure:The western blotting market, by product is segmented into instruments and consumables.Consumables segment is expected to account for the largest share of the market, by product in 2016.This segment is also expected to grow at the highest CAGR during the forecast period.The western blotting instruments are further classified into gel electrophoresis instruments, blotting systems, and imagers.The blotting systems segment is expected to account for the largest share of western blotting instruments market, by type in 2016.
The growth is due to evolution of market owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research reproducibility, and increasing R activity and expenditure in the life sciences industry.Fueled by the growing demand for personalized medicine and structure-based drug design, the global research antibodies and reagents market is expected to witness significant growth in the coming years.The report Research Antibodies & Reagents Market  is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period.Ask for PDF Brochure: –https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793COVID-19 Impact: -The COVID-19 outbreak has boosted research activity due to efforts to understand the dynamics of the infection.We estimate that the major share of research antibody and reagent manufacturing, along with personalized medicine, will grow at a stable pace in the next five years.Due to the increase in research activity, both the availability of funding for research and the demand & manufacturing of reagents and antibodies are expected to grow.As companies after pandemic have scaled up their operations for testing and tracking the infection of COVID-19.The shift in demand for research for COVID-19, neurobiology, and oncology has created a huge scope for testing solutions, such as western blotting, flow cytometry, ELISA, and drugs for researchers and laboratories.Market Segmentation: -Based on product, the research antibodies market is segmented into reagents and antibodies.
The Global Q fever market is expected to grow at CAGR of 7.83% to reach USD 6,249.68 thousand till 2023.Some of the protuberant drivers supporting the growth of the global Q fever market are identified as growth in the prevalence of chronic diseases and the increasing number of patients suffering from various bacterial infections.The rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in the risk factors of Q fever, and globally growing geriatric population are expected to drive the global Q fever market in coming years.Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5490SegmentationGlobal Q fever, by type, segmented into acute and chronic.Chronic is the leading segment, which is growing at the highest CAGR to reach USD 706.20 thousand by the end of 2023.Chronic Q fever is a life threating problem and causes damage to the heart, lungs, liver, brain, and could cause diabetes as well.The major share of the chronic segment is attributed to its high prevalence.Based on diagnosis, Q fever market is segmented into serology tests and others.Under the serology test, Q fever is diagnosed through antibody blood tests, polymerase chain reaction (PCR) tests, immunoperoxidase staining, complement fixation, enzyme-linked immunosorbent assay (ELISA) tests, and other molecular tests.The Q fever market, by treatment, is segmented into antibiotic and surgery.
ANA tests can help doctors to determine autoimmune ailments.A new report on the global anti-nuclear antibody (ANA) testing market, published by Market Research Future (MRFR), estimates that this market could rise at 9.6% CAGR between 2017 and 2023.In terms of value, the market can be worth USD 1300.6 Mn by the end of the forecast period.The primary market driver for the global anti-nuclear antibody (ANA) testing market growth is increasing technological advancement.The increasing use of technology in medical sector is also boosting the anti-nuclear antibody (ANA) testing market.Major brands are investing money in research & development (R) to develop more advanced medical devices or equipment for the market that can elevate the anti-nuclear antibody (ANA) testing market revenue.Anti-nuclear Antibody (ANA) Testing Market SegmentationThe global anti-nuclear antibody (ANA) testing market segmentation encompasses application, end-user, and type.The lupus segment has been sub-segmented into discoid lupus erythematosus, neonatal lupus, subacute cutaneous lupus erythematosus, and systemic lupus erythematosus (SLE).
The global COVID-19 diagnostics market size is expected to reach USD 23.67 billion by 2027 according to a new study by Polaris Market Research.The report “COVID-19 Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Product & Service Type (Instruments, Reagents & Kits, Service); By Sample Type (Nasopharyngeal (NP) Swab, Oropharyngeal (OP) Swab, Nasal Swabs, Blood, Others); By Test Type (Molecular (PCR) Testing, Antigen-based Testing, Antibody (Serology) Testing, Others); By Mode; By End Use; By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.COVID-19 medical tests play an important role in management of coronavirus and thus helping in containing the virus infection.These tests are available as POC and non-POC across various healthcare settings such as hospitals, diagnostic centers, physician clinics, and research laboratories.POC test are comparatively easier than the other swab-based tests but they lack sensitivity and specificity thus providing a non-conclusive result.While these tests are useful in real-time monitoring of infection as a preliminary test, the swab-based tests are necessity for confirmation of COVID-19 infection as they incorporate RT-PCR technology, which provide accurate results.The recent requirements for COVID-19 tests are higher accuracy, faster results, low-cost, and high sensitivity towards coronavirus.Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/covid-19-diagnostics-market/request-for-sampleThe market drivers for COVID-19 diagnostic includes rapidly increasing COVID-19 infections across the globe, increasing number of patients undergoing diagnosis, government initiatives such as Sero testing, increased preference of physicians and patients towards POC testing, and increased requirement for COVID-19 test by non-profit organizations.According to World Health Organization (WHO) as of September there were 29 million cases of COVID-19 infections worldwide, affecting about 213 countries and increasing rapidly.The relaxation in lockdowns across the countries and increasing number of testing is expected to drive the demand for COVID-19 diagnostics market.
Photo by Elizabeth Lopatto / The Verge More that 4,300 SpaceX employees volunteered to be part of a COVID-19 antibody study co-authored by CEO Elon Musk in 2020. The study, which was recently published in the journal Nature Communications, shows evidence that infected people who exhibited milder symptoms developed less of an immunity to COVID-19 than those who got sicker from the disease. The group behind the study found some evidence that suggests there’s a particular threshold of antibodies that could provide immunity, though they wrote that “the precise levels [...] associated with protection from re-infection remain unclear.” Vaccines also produce a much stronger immune response than cases with little to no symptoms, the authors note. They hope that this research, and o... Continue reading…
7
Global Research Antibodies Market: OverviewThe global research antibodies market is anticipated to rise at a notable pace over the forecast period.Hence, this makes for a key factor for continual research to examine the physiology and anatomy of antibodies.The report serves to identify prevailing growth trends based on which projections made.Geographical distribution of the research antibodies market and an analysis of the competitive structure are highlights of the report.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=58524Global Research Antibodies Market: Key TrendsCurrently, pharmaceutical and biopharmaceutical companies are undertaking extensive R activities to introduce novel products.This is aiding growth of research antibodies market.Lastly, novel use of antibodies that are receiving acceptance of accredited bodies is serving to boost the research antibodies market.For example, in a new development, FDA approved the clinical application of DNA-encoded monoclonal antibody therapy as a prevention against Zika virus.Request for Analysis of COVID19 Impact on Research Antibodies Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=58524Global Research Antibodies Market: Regional AnalysisThe global research antibodies market is spread across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.The region being home to large biotechnology and biopharmaceutical companies, along with immense government aid for research are key factors behind exceptional growth of North America antibodies market.Stringent regulations in place for manufacturers of antibodies and due adherence to these regulations accounts for high quality products from the region.
Global cell dissociation market is expected to reach USD 711.78 million by 2027 witnessing market growth at a rate of 13.4% in the forecast period of 2020 to 2027.These cell dissociation reagents are used along with chelator agents during cell passaging.The cell dissociation buffers have collagenolytic and proteolytic properties for the disengagement of cells and tissues from surfaces of the containers to increase the isolation efficiency with high cell viability.Major Market Competitors/Players: Global Cell Dissociation MarketSome of the major players operating in the global cell dissociation market are BD, Thermo Fisher Scientific , F. Hoffmann-La Roche Ltd , GE Healthcare , Merck KGaA, ATCC, REPROCELL Inc., ALSTEM, CellSystems Biotechnologie Vertrieb GmbH, Biological Industries USA, Inc., Pelobiotech, BrainBits, LLC, Labochema, Himedia Laboratories, Biocompare, Pan-Biotech, Gemini Bio-Products,  Miltenyi Biotec, Stemcell Technologies among others.Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cell-dissociation-marketTo avoid the proteolytic effect of trypsin, few commercially available enzyme-free cell dissociation buffers are used in the preservation of the structural integrity of membrane surface proteins for ligand binding flow cytometry and immunohistochemistry.Nevertheless, non-enzyme dissociation buffers are not used in the serial passage of various primary cell cultures and highly adherent cell lines.Market Segmentation: Global Cell Dissociation MarketThe global cell dissociation market is segmented based on product, type, tissue, end user and geographical segments.Based on product, the global cell dissociation market is segmented into enzymatic dissociation products, non-enzymatic dissociation products and instruments & accessories.Enzymatic dissociation products are further sub segmented into collagenase, trypsin, papain, elastase, dnase, hyaluronidase and other enzymes.The global cell dissociation market is segmented into connective tissue, epithelial tissue and others on the basis of tissue.On the basis of type, the global cell dissociation market is segmented into tissue dissociation and cell detachment.On the basis of application, the global cell dissociation market is segmented into antibody production, veterinary applications, cell culture maintenance, immunoassays and others.On the basis of end user, the global cell dissociation market is classified into pharmaceutical & biotechnology companies, research & academic institutes and others.Based on geography the global cell dissociation market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa.Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.Competitive Analysis: Global Cell Dissociation MarketThe global cell dissociation market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.The report includes market shares of cell dissociation market for global, Europe, North America, Asia Pacific and South America.Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cell-dissociation-marketMajor Market Drivers and Restraints:Rising R expenditure in biopharmaceutical companiesIncreasing government funding for cancer researchEmergence of advanced tissue dissociation enzyme productsAcceptance of enzyme-free dissociation products over enzymatic dissociation productsOccurrences of high decontamination with bacteriaAbout Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.
Antibody therapeutics have made it possible to address the hard to target hotspots, rendering the domain of antibody discovery an emerging sector in the pharmaceutical industry; in fact, the antibodies have proven to be promising weapons in the battle against COVID-19 pandemic.Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years.It features an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics.In addition to other elements, the study includes:A detailed overview of the overall landscape of antibody discovery service providers along with the information on a number of relevant parameters.An insightful competitiveness analysis of antibody discovery service providers based on various relevant parameters, such as supplier power and service portfolio specifications.Elaborate profiles of the prominent companies that provide antibody discovery services.A detailed review of the overall landscape of antibody discovery platforms, along with the information on the technology developers.An in-depth analysis of antibody discovery platforms, taking into consideration the supplier power and key technology specifications.Elaborate profiles of the companies providing antibody discovery technologies / platforms.An assessment of antibody discovery service and platform providers’ capability in different regions.An analysis of the partnerships that have been established in the period between 2015 and 2020.An analysis of the investments made in this domain, during the period between 2016 and 2020 (till April), in companies that are engaged in the field of antibody drug discovery.Detailed profiles on the top five therapeutic antibody products, which have generated the highest revenues.A case study on antibody humanization and affinity maturation, highlighting key players, the ongoing research trends and the major challenges in this field.A detailed market forecast, featuring analysis of the financial opportunity within the antibody discovery services market across the following segments:Steps Involved in the Antibody Discovery ProcessAntigen DesigningHit GenerationLead SelectionLead OptimizationLead Characterization Antibody Discovery Method UsedPhage DisplayHybridomaTransgenic AnimalYeast DisplaySingle CellOthers Nature of Antibody GeneratedHumanizedHumanChimericMurine Press Release: Variation 1 (Format 2) Key Geographical Regions North AmericaEuropeAsia Pacific and Rest of the WorldA detailed market forecast, featuring analysis of the financial opportunity within the antibody discovery services market across the following segments:Type of PaymentUpfront PaymentsMilestone Payments Key Geographical Regions North AmericaEuropeAsia Pacific Key companies covered in the report:AbzenaAbwiz BioAragen BioscienceBIOTEMChemPartnerCreative BiolabsDistributed BioHarbour BioMedHD BiosciencesImmunoPrecise AntibodiesIntegral MolecularKymabLakePharmaLigand PharmaceuticalsMorphoSysPX’TherapeuticsSyd LabsViva BiotechWuxi Biologics For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html Other recent offerings:Antibody Contract Manufacturing Market, 2020 – 2030Antibody Drug Conjugates Market (5th Edition), 2019-2030Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market, 2019-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
High target specificity and favorable safety profiles offered by antibody based pharmacological interventions has created a high demand for such molecules; the domain has witnessed an increased inflow of investments and collaboration opportunities.As a result, innovator companies are outsourcing most of their discovery-stage operations to specialty contract research organizations (CROs), which offer a plethora of advanced technologies to cater to the evolving needs.It is also worth highlighting that stakeholders engaged in this domain are actively undertaking initiatives to develop interventions for SARS-CoV-2 virus.To order this 450+ page report, which features 120+ figures and 140+ tables, please visit this link Key Market Insights  Presently, more than 80 players claim to offer services for antibody discovery Over 90% of the aforementioned players provide services for hit generation, followed by those offering services for antibody humanization (58%).Amongst these, phage display is currently the most widely used technique.Majority of partnership deals signed within this domain were licensing agreements (25%), product development and commercialization agreements (24%), and R agreements (18%).
The Global Hematologic Malignancies Therapeutics Market Size is anticipated to reach over USD 87.0 Billion by 2025 according to a new research published by Polaris Market Research.According to an industry report in 2011, Hematological malignancies constituted 9% of all newly diagnosed malignancies in the U.S. specifying that lymphomas are more prevalent than myeloma or leukemias.Hence, considering the aging worldwide population, malignancy type is more probable to become more prevalent.Request for sample copy of this report @ https://www.polarismarketresearch.com/industry-analysis/hematologic-malignancies-therapeutics-market/request-for-sampleThe global Hematologic Malignancies Therapeutics Market growth is majorly driven by the increasing focus on development for novel treatments and growing occurrence of blood cancer.For instance, in 2015, Pfizer announced that its antibody-drug conjugate- inotuzumab has received USFDA approval for acute lymphoblastic leukemia.The Global Hematologic Malignancies Therapeutics Market is segmented on the basis of type, therapy, and geography.The major market share is due to availability of products such as Imbruvica, Rituxan, and Glivec, which are estimated to be the highest revenue generating drugs.The dominance is majorly attributed to the high presence of key market players, availability of branded drugs, established healthcare organization, and increasing government support in the region.
Elon Musk reportedly took a personal interest in the study, and asked researchers to brief himself and top SpaceX executives.
10
Global Monoclonal Antibody Custom Service Market Analytical Surveying Report is added on Marketresearchfuture.com with 85 pages.A separate section with Monoclonal Antibody Custom Service industry key players is included in the report, which provides a comprehensive analysis, cost, gross, Revenue, Product Overview, Specifications, Company Profile and Regional Analysis.Monoclonal Antibody Custom Service Market — HighlightsIt is estimated that monoclonal antibody custom service market is expected to grow at a CAGR 10.84% during the forecast period 2017–2023.These antibodies have tendency to grow indefinitely and are very particular for a location in the body derived from a single clone.Monoclonal antibody custom service offers the development of both rat and mouse hybridomas for the production of custom monoclonal antibodies from synthesized peptide or recombinant protein antigens.These services provide a comprehensive services for antibody cloning, expression, engineering, and purification in addition to custom antibody development for multiple pharmaceutical and biotechnological companies.Request Sample Copy at https://www.marketresearchfuture.com/sample_request/4515Increasing investment in research & development, increasing prevalence of chronic diseases, infections, and rising occurrence of immunological diseases are the key factors driving the market growth.However, high cost of monoclonal antibody services may hinder the growth of market to an extent.Monoclonal Antibody Custom Service Market — Segmentation:The global monoclonal antibody custom service market is segmented on the basis of type, application, and end-users.On the basis of type, the market is segmented into rat custom monoclonal antibody, rabbit custom monoclonal antibody, and others.On the basis of application, the market is classified into diagnostic application, therapeutic application, and protein purification.The biochemical analysis is further segmented into pregnancy, cancer, hormonal disorder, and infectious diseases.
1
Vaccinex stock spiked after reaching two deals with pharmaceutical companies that will use its technology for discovering antibodies.
8
New York, NY 19 Feb 2021: The global COVID-19 diagnostics market size is expected to reach USD 23.67 billion by 2027 according to a new study by Polaris Market Research.The report “COVID-19 Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Product & Service Type (Instruments, Reagents & Kits, Service); By Sample Type (Nasopharyngeal (NP) Swab, Oropharyngeal (OP) Swab, Nasal Swabs, Blood, Others); By Test Type (Molecular (PCR) Testing, Antigen-based Testing, Antibody (Serology) Testing, Others); By Mode; By End Use; By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/covid-19-diagnostics-market/request-for-sample While these tests are useful in real-time monitoring of infection as a preliminary test, the swab-based tests are necessity for confirmation of COVID-19 infection as they incorporate RT-PCR technology, which provide accurate results.The recent requirements for COVID-19 tests are higher accuracy, faster results, low-cost, and high sensitivity towards coronavirus.According to World Health Organization (WHO) as of September there were 29 million cases of COVID-19 infections worldwide, affecting about 213 countries and increasing rapidly.The relaxation in lockdowns across the countries and increasing number of testing is expected to drive the demand for COVID-19 diagnostics market.
Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs.Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this China Biopharmaceutical Contract Manufacturing Market, 2020-2030 The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:Type of Product APIFDF Type of Expression System UsedMammalianMicrobialOthers Scale of OperationPreclinical / ClinicalCommercial Size of ManufacturerSmallMid-sizedLarge / Very Large Type of Biologic Antibody VaccineOthers The China Biopharmaceutical Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: ChemPartner BiologicsJHL BiotechJOINN BiologicsMabPlexMycenax BiotechWuXi AppTec Table of Contents  Preface 2.Executive Summary Introduction Case Study: Comparison of Small Molecules and Large Molecules Competitive Landscape Company Profiles Partnerships Recent Expansions Clinical Trial Analysis Regional Capability Analysis Capacity Analysis Big Pharma Biopharmaceutical Manufacturing Initiatives in China Make Versus Buy Decision Making Framework Market Sizing and Opportunity Analysis  COVID-19 Impact on China Biopharmaceutical CMO Market   SWOT Analysis  Future of the China Biopharmaceutical CMO Market  Interview Transcripts  APPENDIX 1: TABULATED DATA  APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.” The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs.The study also features a detailed analysis of the key drivers and trends related to this evolving domain.In addition to other elements, the study includes:A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).An analysis of the partnerships that have been established in this domain, in the recent past.An analysis of the various expansion initiatives undertaken by the players in this domain.An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Type of ProductHPAPIsHighly Potent Finished Dosage Forms Company SizeSmall-sizedMid-sizedLarge / Very Large Scale of OperationPreclinical / ClinicalCommercial Type of Pharmacological MoleculeSmall MoleculesBiologics Type of Highly Potent Finished Dosage FormInjectablesOral SolidsCreamsOthersKey geographical regionsNorth AmericaEuropeAsia PacificRest of the World The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies:Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals)Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research)Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)Roberto Margarita (Business Development Director, CordenPharma)Allison Vavala (Senior Manager, Business Development, Helsinn)Mark Wright (Site Head, Piramal Healthcare)Javier E. Aznárez Araiz (Business Development Technician, Idifarma) Key companies covered in the reportAbbVie Contract ManufacturingCARBOGEN AMCISCatalentEvonikFormosa LaboratoriesIntasLonzaMabPlexPfizer CentreOne For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html   Other Recent OfferingsAntibody Contract Manufacturing Market, 2020 – 2030Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]  
Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment.Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities.This has led to an increased demand for contract manufacturing service providers in this field.To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:Type of ProductHPAPIsHighly Potent Finished Dosage Forms Company SizeSmall-sizedMid-sizedLarge / Very Large Scale of OperationPreclinical / ClinicalCommercial Type of Pharmacological MoleculeSmall MoleculesBiologics Type of Highly Potent Finished Dosage FormInjectablesOral SolidsCreamsOthers Key geographical regionsNorth AmericaEuropeAsia PacificRest of the World The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030” report features the following companies, which we identified to be key players in this domain: AbbVie Contract ManufacturingCARBOGEN AMCISCatalentEvonikFormosa LaboratoriesIntasLonzaMabPlexPfizer CentreOne Table of Contents  Preface 2.Executive Summary Introduction Market Landscape Company Competitive Analysis HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles Partnerships and Collaborations Recent Expansions Capacity Analysis Market Sizing and Opportunity Analysis Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates  Concluding Remarks  Executive Insights  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html   Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]    The “HPAPI an
The global wearable injectors market is expected to grow significantly over the forecast period.It is estimated that the global wearable injectors market is expected to register a CAGR of ~ 15.2% during the forecast period from 2018 to 2023.For instance, in July 2016, Amgen received US Food and Drug Administration (FDA) approval for its on-body wearable injector, Repatha (evolocumab) Pushtronex system, a human monoclonal antibody injector.Moreover, favorable healthcare investments by government and the rising demand for minimally invasive devices boosts the growth of the market.However, stringent government regulation for product approval and the growing preference for traditional methods of drug delivery may hamper the market growth during the assessment period.SegmentationThe global wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.The market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.The market, by usage, has been segmented into disposable and semi-reusable.The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.Key playersWest Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG are some of the key players in the global wearable injectors market.Regional Market SummaryGeographically, the Americas is anticipated to dominate the global wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure.
High Potency APIs Market OverviewAccording to the latest analysis published by Market Research Future (MRFR), the global High Potency APIs Market is set to strike a CAGR of 8.40% during the forecast period 2018 to 2023.The competitive landscape of the market is highly lucrative and rising investments is prognosticated to boost the manufacturing of HPAPIs.Furthermore, the key players are anticipated to strategize agreements, acquisitions, and partnerships for gaining edge over competitors.The developments witnessed in the healthcare sectors of the fast-developing economies such as China, India, and Japan are forecasted to revolutionize the HPAPI market in the foreseeable future.Nevertheless, lack of global regulatory framework is expected to hold the expansion of the market across the projection period.Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/6679Global High Potency APIs Market – Segmental Analysis:This MRFR’s report offers a detailed segmental analysis of the global high potency APIs market based on product, type and therapeutic area.The rising demand for antibody-drug conjugates (ADCs) is expected to propel the expansion of the biotech segment in the foreseeable future.By type, the market has been segmented into novel or innovative, and generic.The growth of the innovative segment can be ascribed to the availability of massive funds for research & development by the manufacturers.By therapeutic area, the market has been segmented into oncology, glaucoma, hormonal, and others.
More

Top